1. Volume 91, Issue 1, Pages 227-234 (January 2017)
Cardiovascular events and death in Japanese patients with chronic kidney disease 
Kenichi Tanaka, Tsuyoshi Watanabe, Ayano Takeuchi, Yasuo Ohashi, Kosaku Nitta, Tadao Akizawa, Seiichi Matsuo, Enyu Imai, Hirofumi Makino, Akira Hishida 
Kidney International 
Volume 91, Issue 1, Pages (January 2017)
DOI: /j.kint
Copyright © 2016 International Society of Nephrology Terms and Conditions

2. Figure 1 Patient disposition. CV, cardiovascular.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

3. Figure 2
Incidences of cardiovascular events and all-cause death by chronic kidney disease (CKD) stage at baseline in Japanese patients with predialysis CKD. The incidences of cardiovascular events also are shown separately by myocardial infarction, cerebrovascular disease, congestive heart failure, others, and cardiovascular death (others included angina pectoris, sudden death, arrhythmias, chronic arteriosclerosis obliterans, and aortic dissection). eGFR, estimated glomerular filtration rate.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

4. Figure 3
Kaplan–Meier curves for the incidence of cardiovascular events by chronic kidney disease (CKD) stage at baseline in Japanese patients with predialysis CKD. Log-rank P < (no consideration of competing events), and P < (treating noncardiovascular death as a competing event).
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

5. Figure 4
Kaplan–Meier curves for the incidence of cardiovascular events by chronic kidney disease (CKD) stage at baseline in Japanese patients (a) with predialysis CKD and diabetes mellitus (DM) and (b) with predialysis CKD who did not have DM. (a) Log-rank P = (no consideration of competing events), and P = 0.003 (treating noncardiovascular death as a competing event). (b) Log-rank P = (no consideration of competing events), and P = (treating noncardiovascular death as a competing event).
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

6. Figure S1
Kaplan–Meier curves for the incidence of the primary end points (cardiovascular events plus all-cause death) by chronic kidney disease (CKD) stage at baseline unadjusted for confounding factors in Japanese patients with predialysis CKD (without consideration of competing events). Log-rank P < CKD, chronic kidney disease.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

7. Figure S2
Kaplan–Meier curves for the incidence of the primary end points (cardiovascular events plus all-cause death) by chronic kidney disease (CKD) stage at baseline in Japanese patients with predialysis CKD and diabetes mellitus (DM) (without consideration of competing events). Log-rank P =
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

8. Figure S3
Kaplan–Meier curves for the incidence of the primary end points (cardiovascular events plus all-cause death) by chronic kidney disease (CKD) stage at baseline in Japanese patients with predialysis CKD who did not have diabetes mellitus (DM) (without consideration of competing events). Log-rank P =
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions